Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10500329" target="_blank" >RIV/00179906:_____/25:10500329 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/25:10500329 RIV/00216208:11150/25:10500329 RIV/00064165:_____/25:10500329

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Ghbh.H5FIK" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Ghbh.H5FIK</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41408-025-01329-2" target="_blank" >10.1038/s41408-025-01329-2</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up

Popis výsledku v původním jazyce

Peripheral T-cell lymphomas (PTCLs) represent ~10-15% of non-Hodgkin lymphomas. Systemic anaplastic large cell lymphoma (sALCL), a PTCL subtype characterized by universal CD30 expression, is therefore a candidate for CD30-targeted treatment. sALCL is sub-divided by the presence or absence of anaplastic lymphoma kinase (ALK) protein. ALK+ sALCL has a better prognosis than ALK- sALCL and other PTCL subtypes; nevertheless, 5-year overall survival (OS) remains 30-50% in older patients with ALK+ sALCL and those with other unfavorable prognostic factors. Brentuximab vedotin, an antibody-drug conjugate combining an anti-CD30 antibody with microtubule-disrupting agent monomethyl auristatin E, demonstrated high overall response (ORR) and complete remission (CR) rates of 86% and 57%, respectively, in a phase 2 study of patients with relapsed or refractory sALCL, leading to global approval. The efficacy of front-line brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (A + CHP) in previously untreated patients with CD30-positive PTCL has been demonstrated in the phase 3 ECHELON-2 study, which enrolled 452 patients with CD30 + PTCL, of whom 316 (70%) had sALCL. In all patients, progression was reduced by 30% with A + CHP versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.53-0.91, P = 0.008); OS was also superior in patients treated with A + CHP (HR 0.72, 95% CI 0.53-0.99, P = 0.001). Given that ALK status is a significant predictor of outcomes in patients with sALCL, it is important to understand the longer-term impacts of ALK status on treatment outcomes to appropriately guide treatment decisions and management strategies. Here, we present further analysis of ECHELON-2, detailing outcomes in ALK+ and ALK- sALCL subgroups at 5 years&apos; follow-up.

Název v anglickém jazyce

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up

Popis výsledku anglicky

Peripheral T-cell lymphomas (PTCLs) represent ~10-15% of non-Hodgkin lymphomas. Systemic anaplastic large cell lymphoma (sALCL), a PTCL subtype characterized by universal CD30 expression, is therefore a candidate for CD30-targeted treatment. sALCL is sub-divided by the presence or absence of anaplastic lymphoma kinase (ALK) protein. ALK+ sALCL has a better prognosis than ALK- sALCL and other PTCL subtypes; nevertheless, 5-year overall survival (OS) remains 30-50% in older patients with ALK+ sALCL and those with other unfavorable prognostic factors. Brentuximab vedotin, an antibody-drug conjugate combining an anti-CD30 antibody with microtubule-disrupting agent monomethyl auristatin E, demonstrated high overall response (ORR) and complete remission (CR) rates of 86% and 57%, respectively, in a phase 2 study of patients with relapsed or refractory sALCL, leading to global approval. The efficacy of front-line brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (A + CHP) in previously untreated patients with CD30-positive PTCL has been demonstrated in the phase 3 ECHELON-2 study, which enrolled 452 patients with CD30 + PTCL, of whom 316 (70%) had sALCL. In all patients, progression was reduced by 30% with A + CHP versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.53-0.91, P = 0.008); OS was also superior in patients treated with A + CHP (HR 0.72, 95% CI 0.53-0.99, P = 0.001). Given that ALK status is a significant predictor of outcomes in patients with sALCL, it is important to understand the longer-term impacts of ALK status on treatment outcomes to appropriately guide treatment decisions and management strategies. Here, we present further analysis of ECHELON-2, detailing outcomes in ALK+ and ALK- sALCL subgroups at 5 years&apos; follow-up.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood Cancer Journal

ISSN

2044-5385

e-ISSN

2044-5385

Svazek periodika

15

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

129

Kód UT WoS článku

001542583400001

EID výsledku v databázi Scopus

2-s2.0-105012390468